Imunephenotypic quantification of T regulatory cells in dogs with lymphoma submitted to Madison-Wisconsin quimiotherapy associated with a COX-2 inhibitor

• Grant number: 13/07533-4
• Support Opportunities: Scholarships abroad - Research Internship - Doctorate
• Start date: August 05, 2013
• End date: November 04, 2013
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Principal Investigator: Áureo Evangelista Santana
• Grantee: Letícia Abrahão Anai
• Supervisor: Camilo Bulla
• Host Institution: Faculdade de Ciências Agrárias e Veterinárias (FCAV). Universidade Estadual Paulista (UNESP). Campus de Jaboticabal. Jaboticabal , SP, Brazil
• Institution abroad: Mississippi State University (MSU), United States
• Associated to the scholarship: 10/19425-3 - IMUNOPHENOTYPIC QUANTIFICATION OF REGULATORY T CELLS IN DOGS WITH MULTICENTRIC LYMPHOMA SUBMITTED TO CHOP CHEMOTHERAPY PROTOCOL ASSOCIATED OR NOT TO FIROCOXIB, BP.DR

Abstract

Lymphoma is a neoplasia characterized by malignant clonal lymphocites proliferation and originates from the bone marrow, spleen, liver and lymphnodes. However, it can practically evolve from any organ by continuous migration of lymphocites through different organic tissues. Lymphoma is one of the most common malignancies in dogs, accounting for 8,5 to 9% of all canine tumors. T regulatory cells (Tregs) are described as T CD4+ lymphocites which express constitutively the ± chain from the interleukin 2 (IL2) receptor (CD25). It is believed that Tregs regulate the physiological immune response and is involved in a series of infectious, allergic, neoplastic and autoimmune diseases. Involvement in the immunologic process of implants has also been observed. There is evidence that the Tregs subregulate the effective function against tumors, resulting in T cells disfunction in humans and dogs with cancer. A study with Tregs in humans has encouraged similar researches in veterinary medicine and despite the rising number of papers about Tregs in dogs, only a few of them were accomplished with lymphoma cases therefore little results are available. Recent studies suggest that some drugs can be used to extinguish or suppress Tregs function. The increase on the enzyme COX-2 expression by the tumor cells and local inflammatory cells stimulate the development of Tregs. Thus, the treatment with COX-2 inhibitors such as non steroidal anti-inflammatory is a way of inhibiting Tregs. (AU)